Drug Profile


Alternative Names: SB-728-HSC; SB-728-HSPC; SB-728mR-HSPC

Latest Information Update: 12 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sangamo BioSciences
  • Developer City of Hope National Medical Center; Sangamo Therapeutics; University of Southern California
  • Class Cell therapies; Stem cell therapies; Zinc finger DNA binding proteins
  • Mechanism of Action CCR5 receptor modulators; Cell replacements; Gene silencing
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 01 Jul 2015 Phase-I clinical trials in HIV infections in USA (Parenteral, Infusion)
  • 01 Feb 2015 Sangamo Biosciences plans a phase-I trial for HIV-infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top